Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Active Treatment-controlled, Evaluator-blinded Multicenter Study to Establish the Superiority of Hyalofast® With BMAC in the Treatment of Articular Knee Cartilage Defect Lesions in Comparison to Control

NCT02659215 is registered in ClinicalTrials.gov with Anika Therapeutics, Inc. as lead sponsor.

NCT NCT02659215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02659215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Active Treatment-controlled, Evaluator-blinded Multicenter Study to Establish the Superiority of Hyalofast® With BMAC in the Treatment of Articular Knee Cartilage Defect Lesions in Comparison to Control
Lead sponsor
Anika Therapeutics, Inc.
Phase
Not applicable
Overall status
Active, not recruiting
Start date
December 31, 2015
Completion date
June 30, 2026
Enrollment
200 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

defect of articular cartilage